1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial




descargar 39.44 Kb.
título1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial
fecha de publicación26.02.2016
tamaño39.44 Kb.
tipoDocumentos
b.se-todo.com > Contabilidad > Documentos
BIBLIOGRAFIA
(1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial.
(2) Janssen lanza Esquizofrenia 24x7, web para comprender la enfermedad PMFARM 12/11/2013,(Consultado el 18/12/2013) http://www.pmfarma.es/noticias/17566-janssen-lanza-esquizofrenia-24x7-web-para-comprender-la-enfermedad.html
(3) Joseph J. (2010) Genetic Research in Psychiatry and Psychology: A critical overview. En Hood KE, Halpern CT, Greenberg G, & Lerner RM. (Editors) Handbook of Developmental Science, Behavior, and Genetics. Cap 18, p.557-625. USA: John Wiley & Sons.
(4) Nestler E, Hyman S. (2002) Molecular Neuropharmacology. USA: McGraw-Hill Medical. (p 392)
(5) Stahl SM. (2012) Psicofarmacología Esencial de Stahl Guía del Prescriptor 4ª Edición. España: Aula Médica.
(6) van Os J, Howes OD. (2012) Antipsychotic drugs for prevention of relapse. The Lancet Psychiatry. Vol 379 June 2, 2030-2031.
(7) Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti et al. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis Lancet 2012; Pub. online May 3. DOI: 10.1006/S0140-6736(12)60239-6
(8) Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. (2013) Recovery in Remitted First- Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry. Sep 1;70(9), 913-20.
(9) Harrow M, Jobe TH. (2007) Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study The Journal of nervous and mental disease 195, (5), 406-14.
(10) Harrow M, Jobe TH. & Faull RN. (2012) Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study Psychological Medicine, 42, 2145- 2155.
(11) Harrow M. Jobe TH. (2013) Does Long-Term Treatment of Schizofrenia Whith ntipsychotic

Medications Facilitate Recovery? Schizophr Bull. 2013 Sep;39(5):962-5.
(12) McGorry P, Alvarez-Jimenez M. & Killackey E. (2013) Antipsychotics in First-Episode Psychosis: Less Is More. JAMA Psychiatry. 70(9): 898-900.
(13) Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. Feb;64(2): 2007,242-9.
(14) American Diabetes Association (2004). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27,2,596-601.
(15) Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J & al. Antipsychotics and theRisk of Type 2 Diabetes Mellitus in Children and Youth JAMA Psychiatry 2013;70(10):1067-1075.
(16) Artaloytia JF, Arango C, Lahti A, Sanz J, Pascual A, Cubero P, et al. (2006) Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 2006; 163: 488–93.

(17) Takeuchi H, Suzuki T, Remington G, Robert R, Bies RR, Abe T. et al. (2013) Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: An open-label, randomized, controlled, pilot study. Schizophrenia Bulletin, 39(5), 993-998.
(18) Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. (2011) Long-term Antipsychotic

Treatment and Brain Volumes A Longitudinal Study of First-Episode Schizophrenia. Arch Gen

Psychiatry. 68(2), 128-137.
(19) Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q. Sampson AR, Lewis DA (2007) Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 32: 1216-23
(20) Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies Neuroscience & Biobehavioral Reviews Volume 37, Issue 8, September 2013, Pages 1680–1691.
(21) Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK et al. (2013). Comparison of longerterm safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise stratified randomization. J Clin Psychiatry. Jan;74(1):10-8.
(22) Weinmann S, & Aderhold V. (2010). Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis: Psychological, Social and Integrative Approaches, 2, 50–69.
(23) Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (CATIE Investigators) (2005) Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia N Engl J Med 2005; 353:1209-1223.
(24) Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et a. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) Arch Gen Psychiatry 2006;
63 (10): 1079-87. (25) Lewis S, Lieberman J. (2008) CATIE and CUtLASS: can we handle the truth? The British Journal of Psychiatry 192: 161-163.
(26) Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. ( EUFEST Study Group) (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet. Mar 29;371(9618):1085-97.
(27) Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. (2009) Second-generation versus first generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet. Jan 3;373(9657):31-41.
(28) Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis Lancet Vol.382 September 14, 951-62.
(29) Moncrieff J, Cohen D, Mason JP.(2009) The subjective experience of taking antipsychotic

medication: a content analysis of Internet data. Acta Psychiatr Scand. Aug;120(2): 102-11.
(30) Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. (CATIE Investigators) (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007 Jun;64(6): 633-47.
(31) Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker, SM.D.; Richard WW, et al.

Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST) Am J Psychiatry 2009;166:675-682.

(32) Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. (2011) Oral versus depot

antipsychotic drugs for schizophrenia A critical systematic review and meta-analysis of randomised long termtrials Schizophrenia Research 127,83–92.
(33) Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al (2013) Efficacy andeffectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs J Clin Psychiatry. Jun;74(6):568-75.
(34) Fernández Sánchez A, Pinto-Meza A, Haro JM. (2009) Comparación de la eficacia de las formas farmacéuticas de liberación retardada (depot) versus las formas farmacéuticas orales de los antipsicóticos (típicos y atípicos), comercializados en Cataluña, en pacientes con un diagnóstico de esquizofrenia Madrid: Colección: Informes, estudios e investigación / Ministerio de Ciencia e Innovación / Informes de Evaluación de Tecnologías Sanitarias; AATRM 2007/17.
(35) Zhornitsky S, Stip E. (2012) Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review . Schizophrenia Research and Treatment Volume 2012, Article ID 407171.

http://dx.doi.org/10.1155/2012/407171
(36) Gentile S. (2013) Adverse Effects Associated with Second-Generation Antipsychotic Long-Acting Injection Treatment: A Comprehensive Systematic Review. Pharmacotherapy 33(10):1087–1106) doi: 10.1002/phar.1313
(37) Grupo de trabajo de la GPC sobre la Esquizofrenia y el Trastorno Psicótico Incipiente (2009). Guía de Práctica Clínica sobre la Esquizofrenia y el Trastorno Psicótico Incipiente. Madrid: Ministerio de Sanidad y Consumo. GPC: AATRM. Nº 2006/05-2.
(38) Austin SF, Mors O, Secher RG, Hjorthøj CR, Albert N, Bertelsen M, et al.(2013) Predictors of recovery in first episode psychosis: the OPUS cohort at 10 year follow-up Schizophrenia Research. Oct;150(1):163-8.
(39) Aminoff K, Boevink W, Crepaz-Keay D, Daumerie N, Finkelstein C, Gauci D et al. (2010)

Empoderamiento del usuario de salud mental El empoderamiento no es un destino, sino un camino.Declaración de la Oficina Regional para Europa de la OMS Oficina Regional para Europa de la OMS.
(40) Slade, M. (2009) Personal Recovery and Mental Illness Paperback: A Guide for Mental HealthProfessionals. UK: Cambridge Univ Press.

(41) Morrison A, Bentall R, Renton JC, Dunn H, Williams S. (2012) Terapia cognitiva de la psicosis: Un enfoque basado en la formulación. España: Herder Editorial.
(42) Zipursky RB, Reilly TJ, Murray R.M: The Myth of Schizophrenia as a Progressive Brain Disease Schizophr Bull (2012) doi: 10.1093/schbul/sbs135.
(43) Corstens D, Longden E, Rydinger B, Bentall R, van Os J. Treatment of hallucinations: A comment Psychosis, 2013 Vol. 5, No. 1, 98-102.
(44) Morrison AP, Hutton P, Wardle M, Spencer H, Barratt S, Brabban A et al. (2012). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial Psychol Med. 2012 May; 42(5):1049-56.
(45) Seikkula J, Aaltonen J, Alakare B, Haarakangas K, Kera¨Nen J, Lehtinen K.(2006) Five-year experience of first-episode nonaffective psychosis in open-dialogue approach. Psychotherapy Research 16,214–28.
(46) Ley de Autonomía del Paciente, 41/2002 de 14 de Noviembre.

(47) Candia PC, Barba AC. (2011) Mental capacity and consent to treatment in psychiatric patients: the state of research. Current Opinion in Psychiatry 24, 2011, p. 442-446.
(48) The Royal College of Psychiatrists. Fair Deal for mental health manifesto. (consultado el

15/12/2013).Disponible en: http://www.rcpsych.ac.uk/pdf/Fair%20Deal%20manifesto%20%28full%20-%201st%20July2009%29.pdf.pdf
(49 ) Read J. (2008) Psychiatric drugs. Key issues and service user perspectives. UK: Palgrave.

(50) Morrison A, Hutton P. Shiers D, Turkington D. (2012) Antipsychotics: is it time to introduce patient choice? BJP 201,83-84.
(51) Valverde MA. (2013) Curar con lo último: el palmitato de paliperidona. Rev. Norte de Salud

Mental. Vol XI;46:59-47.
(52) Goldacre B. Mala farma. Cómo las empresas farmacéuticas engañan a los médicos y perjudican alos pacientes. España: Paidós, 2013.
(53) Moynihan A, Cassels R. (2006) Medicamentos que nos enferman e industrias farmacéuticas que nos convierten en pacientes. España: Contrapunto.
(54) Cosgrove L, Krimsky S. (2012) A Comparison of DSM-IV and DSM-5 Panel Members’ Financial Associations with Industry: A Pernicious Problem Persists. PLoS Med. 9 (3): e1001190. doi:10.1371/ journal.pmed.1001190.

similar:

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconHoja de información para los pacientes y familiares

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconGuía para pacientes

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconHm universitario Madrid organiza unas Jornadas Científicas de Actualización...

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconOrientaciones familiares para fomentar hábitos alimenticios saludables

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconPlan de manejo de conservación y uso sustentable para la reserva marina de galápagos

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconModelo o guia de tutela para medicamentos nuevos y/o que no estan...

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconEducación para la sostenibilidad: Un enfoque ecológico

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconUltrasonido endoscópico y cáncer gástrico. Una alternativa para mejorar...

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial iconEl uso de ondas de choque para el tratamiento de la osteonecrosis...

1) Díaz Marsá, Marina. I. (2013) Afrontando la esquizofrenia guía para pacientes y familiares. Madrid: Enfoque Editorial icon¿Cuáles son las señales tempranas de la esquizofrenia?




Todos los derechos reservados. Copyright © 2019
contactos
b.se-todo.com